Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Plasma Cell Leukemia

Plasma Cell Leukemia

13

Pipeline Programs↗

12

Active Trials↗

5

Companies Involved↗

Plasma Cell Leukemia is an emerging landscape with 13 programs across 5 companies. The most active players are Nanjing IASO Biotechnology Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

83/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Nanjing IASO Biotechnology Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical1

CT0594CP

The First Affiliated Hospital of Soochow University

Phase 12

CAR-T（RD140 Injection）

Peking University People's Hospital

CAR-GPRC5D

Nanjing IASO Biotechnology Co., Ltd.

Phase 210

Dexamethasone

Aspen Global Incorporated

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Daratumumab

Johnson & Johnson

Carfilzomib

Virionyx Corporation Limited

BCMA CAR-T

Hebei Senlang Biotechnology Inc., Ltd.

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

11programs

Small molecule545%

Cell therapy436%

Monoclonal antibody218%

Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

20

clinical trials

Recruiting9 · 45%

Completed5 · 25%

Not yet recruiting2 · 10%

Unknown status2 · 10%

Withdrawn1 · 5%

Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

A Study of CT0596 in Plasma Cell Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06988059·27 enrolled

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Recruiting·—·Phase 1·NCT05219721·18 enrolled

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07106684·20 enrolled

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05979363·20 enrolled

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT05822037·6 enrolled

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Recruiting·SShanghai Changzheng Hospital·Phase 1·NCT06718270·24 enrolled

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Recruiting·NNanjing IASO Biotechnology Co., Ltd.·Phase 1·NCT05759793·12 enrolled

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT06730256·24 enrolled

Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT07605416·74 enrolled

A Prospective, Single-center, Phase II Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Newly Diagosed Primary Plasma Cell Leukemia

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05870917·20 enrolled

Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05054478·29 enrolled

An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Not yet recruiting·PPeking University People's Hospital·Phase 1·NCT06655519·12 enrolled

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01372540·76 enrolled

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00258245·5 enrolled

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Completed·MMayo Clinic·Phase 2·NCT02547662·17 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)